NK521 Cell Injection

BIOLOGICAL2 trials

Sponsors

Base Therapeutics (Shanghai) Co., Ltd.

Conditions

Advanced Solid TumorsHepatocellular Carcinoma (HCC)Malignant AscitesOvarian Cancer

Early Phase 1

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

RecruitingNCT07561437

Base Therapeutics (Shanghai) Co., Ltd.Advanced Solid Tumors

Start: 2026-03-09End: 2028-10-01Target: 18Updated: 2026-05-01

NK521 in the Treatment of Advanced Solid Tumors

Not yet recruitingNCT07657416

Base Therapeutics (Shanghai) Co., Ltd.Hepatocellular Carcinoma (HCC), Malignant Ascites, Ovarian Cancer

Start: 2026-06-01End: 2028-07-01Target: 18Updated: 2026-06-18